Applications of Clinical Dopamine Imaging

Neuroimaging Clinics of North America

Volumn 16, Issue 4, 2006, Pages 553-573

  Lindsey, Kimberly P ^a,b   Gatley, S John ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; CARBIDOPA; CLORGYLINE C 11; CLOZAPINE; DIHYDROTETRABENAZINE C 11; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; EPIDEPRIDE I 123; FALLYPRIDE F 18; FLUOROATECH; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; NEUROLEPTIC AGENT; NOMIFENSINE; OLANZAPINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; RECEPTOR SUBTYPE; RISPERIDONE; SELEGILINE C 11; TECHNEPINE; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ALCOHOLISM; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COMPULSION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; IMAGE QUALITY; LIGAND BINDING; MAJOR DEPRESSION; MESOCORTICAL PATHWAY; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULAR IMAGING; MOTOR DYSFUNCTION; NERVE TRACT; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OBESITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA; SYNAPSE VESICLE; TISSUE TRANSPLANTATION;

BRAIN; DOPAMINE; HUMANS; LIGANDS; MENTAL DISORDERS; MOVEMENT DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 37849187176     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2006.06.003     Document Type: Review

References (185)

1. Garnett E.S., Nahmias C., and Firnau G. Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11 1 Suppl (1984) 174-179
2. Nahmias C., Garnett E.S., Firnau G., et al. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69 3 (1985) 223-230
3. Wolf A.P., and Fowler J.S. Positron emission tomography: biomedical research and clinical application. Neuroimaging Clin N Am 5 1 (1995) 87-101
4. Fowler J.S., and Wolf A.P. The heritage of radiotracers for positron emission tomography. Acta Radiol Suppl 374 (1990) 13-16
5. Chan G.L., Holden J.E., Stoessl A.J., et al. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40 2 (1999) 283-289
6. Vander Borght T.M., Sima A.A., Kilbourn M.R., et al. [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68 3 (1995) 955-962
7. Kung H.F., Kim H.J., Kung M.P., et al. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 23 11 (1996) 1527-1530
8. Madras B.K., Jones A.G., Mahmood A., et al. Technepine: a high-affinity 99m-technetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 22 3 (1996) 239-246
9. Meltzer P.C., Blundell P., Zona T., et al. A second-generation 99m-technetium single photon emission computed tomography agent that provides in vivo images of the dopamine transporter in primate brain. J Med Chem 46 16 (2003) 3483-3496
10. Innis R.B., Seibyl J.P., Scanley B.E., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90 24 (1993) 11965-11969
11. Van Laere K., De Ceuninck L., Dom R., et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 31 8 (2004) 1119-1127
12. Johannsen B., and Pietzsch H.J. Development of technetium-99m-based CNS receptor ligands: have there been any advances?. Eur J Nucl Med Mol Imaging 29 2 (2002) 263-275
13. Kung H.F., Kung M.P., and Choi S.R. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 33 1 (2003) 2-13
14. Wong D.F., Yung B., Dannals R.F., et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse 15 2 (1993) 130-142
15. Farde L., Halldin C., Stone-Elander S., et al. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 92 3 (1987) 278-284
16. Abi-Dargham A., Martinez D., Mawlawi O., et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20 2 (2000) 225-243
17. Okubo Y., Suhara T., Suzuki K., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 6617 (1997) 634-636
18. Karlsson P., Farde L., Halldin C., et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159 5 (2002) 761-767
19. Andrews T.C., Weeks R.A., Turjanski N., et al. Huntington's disease progression: PET and clinical observations. Brain 122 Pt 12 (1999) 2353-2363
20. Ginovart N., Lundin A., Farde L., et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120 Pt 3 (1997) 503-514
21. Weeks R.A., Piccini P., Harding A.E., et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40 1 (1996) 49-54
22. Sedvall G., Karlsson P., Lundin A., et al. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 243 5 (1994) 249-255
23. Guo N., Hwang D.R., Lo E.S., et al. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 28 9 (2003) 1703-1711
24. Ouchi Y., Kanno T., Okada H., et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann Neurol 46 5 (1999) 723-731
25. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 3 (2000) 423-451
26. Sanchez-Pernaute R., Brownell A.L., and Isacson O. Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration. Neurotoxicology 23 4-5 (2002) 469-478
27. Garnett E.S., Firnau G., and Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 305 5930 (1983) 137-138
28. Eckert T., and Eidelberg D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2 2 (2005) 361-371
29. Au W.L., Adams J.R., Troiano A.R., et al. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 134 1 (2005) 24-33
30. Kemp P.M. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. Nucl Med Commun 26 2 (2005) 87-96
31. Ravina B., Eidelberg D., Ahlskog J.E., et al. The role of radiotracer imaging in Parkinson disease. Neurology 64 2 (2005) 208-215
32. Fischman A.J. Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol Clin North Am 43 1 (2005) 93-106
33. Fukuyama H. Functional brain imaging in Parkinson's disease-overview. J Neurol 251 Suppl 7 (2004) vII1-vII3
34. Asenbaum S., Brucke T., Pirker W., et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 38 1 (1997) 1-6
35. Frost J.J., Rosier A.J., Reich S.G., et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34 3 (1993) 423-431
36. Tissingh G., Bergmans P., Booij J., et al. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 245 1 (1998) 14-20
37. Marek K.L., Seibyl J.P., Zoghbi S.S., et al. [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 1 (1996) 231-237
38. Brucke T., Wenger S., Asenbaum S., et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 60 (1993) 494-500
39. Brucke T., Asenbaum S., Pirker W., et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50 (1997) 9-24
40. van Royen E., Verhoeff N.F., Speelman J.D., et al. Multiple system atrophy and progressive supranuclear palsy: diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 50 5 (1993) 513-516
41. Buck A., Westera G., Sutter M., et al. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med 36 7 (1995) 1196-1200
42. Pirker W., Asenbaum S., Wenger S., et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 38 11 (1997) 1711-1717
43. Verhoeff N.P.L.G., Speelman J.D., Kuiper M.A., et al. Clinical significance of dopamine D2-receptor imaging with [123I]-iodobenzamide SPECT in patients with parkinsonian syndromes. In: De Deyn P.P., Dierckx R.A., Alavi A., et al. (Eds). A textbook of SPECT in neurology and psychiatry (1997), Libbey, London 149-165
44. Thobois S., Guillouet S., and Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin 31 5 (2001) 321-340
45. Chabriat H., Levasseur M., Vidailhet M., et al. In vivo SPECT imaging of D2 receptor with iodine-iodolisuride: results in supranuclear palsy. J Nucl Med 33 8 (1992) 1481-1485
46. Churchyard A., Donnan G.A., Hughes A., et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 34 2 (1993) 219-226
47. Schulz J.B., Klockgether T., Petersen D., et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 57 9 (1994) 1047-1056
48. Verhoeff N.P. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology (Berl) 147 3 (1999) 217-249
49. Stoffers D., Booij J., Bosscher L., et al. Early stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging 32 6 (2005) 689-695
50. Brooks D.J., Ibanez V., Sawle G.V., et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28 4 (1990) 547-555
51. Brooks D.J., Salmon E.P., Mathias C.J., et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113 Pt 5 (1990) 1539-1552
52. Broussolle E., Dentresangle C., Landais P., et al. The relation of putamen and caudate nucleus 18F-dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 166 2 (1999) 141-151
53. Leenders K.L., Palmer A.J., Quinn N., et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49 8 (1986) 853-860
54. Vingerhoets F.J., Schulzer M., Calne D.B., et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol 41 1 (1997) 58-64
55. Marek K., Jennings D., and Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol 53 Suppl 3 (2003) S160-S166 [discussion: S166-9]
56. Nurmi E., Ruottinen H.M., Bergman J., et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 4 (2001) 608-615
57. Morrish P.K., Rakshi J.S., Bailey D.L., et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64 3 (1998) 314-319
58. Eshuis S.A., Maguire R.P., Leenders K.L., et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging 33 2 (2006) 200-209
59. Piccini P. Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 17 4 (2004) 459-466
60. Piccini P., Pavese N., and Brooks D.J. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53 5 (2003) 647-653
61. Whone A.L., Moore R.Y., Piccini P.P., et al. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 53 2 (2003) 206-213
62. Strafella A.P., Ko J.H., Grant J., et al. Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study. Eur J Neurosci 22 11 (2005) 2946-2952
63. Brooks D.J. Positron emission tomography imaging of transplant function. NeuroRx 1 4 (2004) 482-491
64. Anderson K.E. Huntington's disease and related disorders. Psychiatr Clin North Am 28 1 (2005) 275-290
65. Rosas H.D., Feigin A.S., and Hersch S.M. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 1 2 (2004) 263-272
66. Rego A.C., and de Almeida L.P. Molecular targets and therapeutic strategies in Huntington's disease. Curr Drug Targets CNS Neurol Disord 4 4 (2005) 361-381
67. Lawrence A.D., Weeks R.A., Brooks D.J., et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121 Pt 7 (1998) 1343-1355
68. Turjanski N., Weeks R., Dolan R., et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas: a PET study. Brain 118 Pt 3 (1995) 689-696
69. Backman L., and Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. Scand J Psychol 42 3 (2001) 287-296
70. van Oostrom J.C., Maguire R.P., Verschuuren-Bemelmans C.C., et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 65 6 (2005) 941-943
71. Antonini A., Leenders K.L., Spiegel R., et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119 Pt 6 (1996) 2085-2095
72. Ichise M., Toyama H., Fornazzari L., et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 34 8 (1993) 1274-1281
73. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 3 (2003) 403-414
74. Nakamura T., Dhawan V., Chaly T., et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 50 2 (2001) 181-187
75. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 10 (2001) 710-719
76. Lindvall O., and Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 127 (2000) 299-320
77. Furtado S., Sossi V., Hauser R.A., et al. Positron emission tomography after fetal transplantation in Huntington's disease. Ann Neurol 58 2 (2005) 331-337
78. Seeman P., and Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 4194 (1975) 1217-1219
79. Parsey R.V., and Mann J.J. Applications of positron emission tomography in psychiatry. Semin Nucl Med 33 2 (2003) 129-135
80. Abi-Dargham A., and Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20 1 (2005) 15-27
81. Sedvall G., Pauli S., Karlsson P., et al. PET imaging of neuroreceptors in schizophrenia. Eur Neuropsychopharmacol 5 Suppl (1995) 25-30
82. Abi-Dargham A., Mawlawi O., Lombardo I., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 9 (2002) 3708-3719
83. Seeman P., Bzowej N.H., Guan H.C., et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1 1 (1987) 5-15
84. Czudek C., and Reynolds G.P. Binding of [11C]SCH 23390 to post-mortem brain tissue in schizophrenia. Br J Pharmacol 93 Suppl (1988) 166P
85. Knable M.B., Hyde T.M., Herman M.M., et al. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 36 12 (1994) 827-835
86. Hirvonen J., van Erp T.G., Huttunen J., et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62 4 (2005) 371-378
87. Seeman P., Chau-Wong M., Tedesco J., et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72 11 (1975) 4376-4380
88. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 4238 (1976) 481-483
89. Farde L., Wiesel F.A., Halldin C., et al. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45 1 (1988) 71-76
90. Laruelle M., Kegeles L.S., and Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003 (2003) 138-158
91. Laruelle M., Frankle W.G., Narendran R., et al. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 27 Suppl A (2005) S16-S24
92. Farde L., Nordstrom A.L., Nyberg S., et al. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55 Suppl B (1994) 67-69
93. Kessler R.M., Ansari M.S., Riccardi P., et al. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30 12 (2005) 2283-2289
94. Laruelle M., Abi-Dargham A., van Dyck C.H., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93 17 (1996) 9235-9240
95. Abi-Dargham A., Gil R., Krystal J., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155 6 (1998) 761-767
96. Breier A., Su T.P., Saunders R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94 6 (1997) 2569-2574
97. Bertolino A., Breier A., Callicott J.H., et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 22 2 (2000) 125-132
98. Abi-Dargham A., Rodenhiser J., Printz D., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97 14 (2000) 8104-8109
99. Reith J., Benkelfat C., Sherwin A., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91 24 (1994) 11651-11654
100. Hietala J., Syvalahti E., Vuorio K., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346 8983 (1995) 1130-1131
101. Hietala J., Syvalahti E., Vilkman H., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35 1 (1999) 41-50
102. Lindstrom L.H., Gefvert O., Hagberg G., et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46 5 (1999) 681-688
103. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5 3 (2002) 267-271
104. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23 2 (1997) 167-174
105. Elkashef A.M., Doudet D., Bryant T., et al. 6-(18)F-DOPA PET study in patients with schizophrenia: positron emission tomography. Psychiatry Res 100 1 (2000) 1-11
106. Brunswick D.J., Amsterdam J.D., Mozley P.D., et al. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 160 10 (2003) 1836-1841
107. Argyelan M., Szabo Z., Kanyo B., et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 89 1-3 (2005) 115-123
108. Szabo Z., Argyelan M., Kanyo B., et al. [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]. Neuropsychopharmacol Hung 6 2 (2004) 79-81
109. Meyer J.H., Goulding V.S., Wilson A.A., et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 163 1 (2002) 102-105
110. Kugaya A., Seneca N.M., Snyder P.J., et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28 2 (2003) 413-420
111. Dougherty D.D., Bonab A.A., Spencer T.J., et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354 9196 (1999) 2132-2133
112. Krause K.H., Dresel S.H., Krause J., et al. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27 7 (2003) 605-613
113. Cheon K.A., Ryu Y.H., Kim Y.K., et al. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30 2 (2003) 306-311
114. van Dyck C.H., Quinlan D.M., Cretella L.M., et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159 2 (2002) 309-312
115. Jucaite A., Fernell E., Halldin C., et al. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57 3 (2005) 229-238
116. Vles J.S., Feron F.J., Hendriksen J.G., et al. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 34 2 (2003) 77-80
117. Dresel S., Krause J., Krause K.H., et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27 10 (2000) 1518-1524
118. Spencer T.J., Biederman J., Madras B.K., et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 57 11 (2005) 1293-1300
119. Madras B.K., Miller G.M., and Fischman A.J. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57 11 (2005) 1397-1409
120. Volkow N.D., Wang G.J., Fowler J.S., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155 10 (1998) 1325-1331
121. Schneier F.R., Liebowitz M.R., Abi-Dargham A., et al. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157 3 (2000) 457-459
122. Tiihonen J., Kuikka J., Bergstrom K., et al. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154 2 (1997) 239-242
123. Coupland N.J. Social phobia: etiology, neurobiology, and treatment. J Clin Psychiatry 62 Suppl 1 (2001) 25-35
124. Farde L., Gustavsson J.P., and Jonsson E. D2 dopamine receptors and personality traits. Nature 385 6617 (1997) 590
125. Breier A., Kestler L., Adler C., et al. Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 155 10 (1998) 1440-1442
126. Laakso A., Vilkman H., Kajander J., et al. Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry 157 2 (2000) 290-292
127. Sekine Y., Minabe Y., Ouchi Y., et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160 9 (2003) 1699-1701
128. Volkow N.D., Chang L., Wang G.J., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158 12 (2001) 2015-2021
129. Volkow N.D., Chang L., Wang G.J., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158 3 (2001) 377-382
130. Volkow N.D., Chang L., Wang G.J., et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21 23 (2001) 9414-9418
131. Malison R.T., Best S.E., Wallace E.A., et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology (Berl) 122 4 (1995) 358-362
132. Volkow N.D., Wang G.J., Fowler J.S., et al. Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc Natl Acad Sci USA 93 19 (1996) 10388-10392
133. Volkow N.D., Wang G.J., Fischman M.W., et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386 6627 (1997) 827-830
134. Volkow N.D., Fowler J.S., Ding Y.S., et al. Imaging the neurochemistry of nicotine actions: studies with positron emission tomography. Nicotine Tob Res 1 Suppl 2 (1999) S127-S132 [discussion: S139-140]
135. Volkow N.D., Wang G.J., Fischman M.W., et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 67 12 (2000) 1507-1515
136. Howell L.L., and Wilcox K.M. The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 298 1 (2001) 1-6
137. Volkow N.D., Wang G.J., Fowler J.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 20 9 (1996) 1594-1598
138. Laine T.P., Ahonen A., Torniainen P., et al. Dopamine transporters increase in human brain after alcohol withdrawal. Mol Psychiatry 4 2 (1999) 189-191
139. Tiihonen J., Kuikka J., Bergstrom K., et al. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1 7 (1995) 654-657
140. Hietala J., West C., Syvalahti E., et al. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology (Berl) 116 3 (1994) 285-290
141. Repo E., Kuikka J.T., Bergstrom K.A., et al. Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacology (Berl) 147 3 (1999) 314-318
142. Heinz A., Ragan P., Jones D.W., et al. Reduced central serotonin transporters in alcoholism. Am J Psychiatry 155 11 (1998) 1544-1549
143. Volkow N.D., Wang G.J., Maynard L., et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 116 3 (2002) 163-172
144. Wang G.J., Volkow N.D., Logan J., et al. Brain dopamine and obesity. Lancet 357 9253 (2001) 354-357
145. Yasuno F., Suhara T., Sudo Y., et al. Relation among dopamine D(2) receptor binding, obesity and personality in normal human subjects. Neurosci Lett 300 1 (2001) 59-61
146. Kuikka J.T., Tammela L., Karhunen L., et al. Reduced serotonin transporter binding in binge eating women. Psychopharmacology (Berl) 155 3 (2001) 310-314
147. Matochik J.A., London E.D., Yildiz B.O., et al. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab 90 5 (2005) 2851-2854
148. Pannacciulli N., Del Parigi A., Chen K., et al. Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage 31 4 (2006) 1419-1425
149. Hesse S., Muller U., Lincke T., et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res 140 1 (2005) 63-72
150. Malison R.T., McDougle C.J., van Dyck C.H., et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 152 9 (1995) 1359-1361
151. Singer H.S., Hahn I.H., and Moran T.H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 30 4 (1991) 558-562
152. Singer H.S., Szymanski S., Giuliano J., et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159 8 (2002) 1329-1336
153. Wolf S.S., Jones D.W., Knable M.B., et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 273 5279 (1996) 1225-1227
154. Wong D.F., Singer H.S., Brandt J., et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 38 8 (1997) 1243-1247
155. Albin R.L., Koeppe R.A., Bohnen N.I., et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 61 3 (2003) 310-315
156. George M.S., Robertson M.M., Costa D.C., et al. Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 55 4 (1994) 193-203
157. Turjanski N., Sawle G.V., Playford E.D., et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 57 6 (1994) 688-692
158. Meyer P., Bohnen N.I., Minoshima S., et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology 53 2 (1999) 371-374
159. Acton P.D., Meyer P.T., Mozley P.D., et al. Simplified quantification of dopamine transporters in humans using [99mTc]TRODAT-1 and single-photon emission tomography. Eur J Nucl Med 27 11 (2000) 1714-1718
160. Bao S.Y., Wu J.C., Luo W.F., et al. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 10 4 (2000) 200-203
161. Weng Y.H., Kao P.F., Tsai C.H., et al. Dopamine deficiency in rubral tremor caused by midbrain hemangioma: case report. Chang Gung Med J 23 8 (2000) 485-491
162. Huang W.S., Lin S.Z., Lin J.C., et al. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med 42 9 (2001) 1303-1308
163. Shyu W.C., Lin S.Z., Chiang M.F., et al. Early onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. Parkinsonism Relat Disord 11 3 (2005) 173-180
164. Krause K.H., Dresel S.H., Krause J., et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285 2 (2000) 107-110
165. Soyka M., Dresel S., Horak M., et al. PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome. World J Biol Psychiatry 1 4 (2000) 215-218
166. Tzen K.Y., Lu C.S., Yen T.C., et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med 42 3 (2001) 408-413
167. Yen T.C., Lu C.S., Tzen K.Y., et al. Decreased dopamine transporter binding in Machado-Joseph disease. J Nucl Med 41 6 (2000) 994-998
168. Yen T.C., Tzen K.Y., Chen M.C., et al. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. J Nucl Med 43 2 (2002) 153-159
169. Krause K.H., Dresel S., Krause J., et al. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/hyperactivity disorder: positive effect of methylphenidate. J Neurol 249 8 (2002) 1116-1118
170. Lu C.S., Chang H.C., Kuo P.C., et al. The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 10 6 (2004) 369-373
171. Lu C.S., Wu Chou Y.H., Kuo P.C., et al. The parkinsonian phenotype of spinocerebellar ataxia type 2. Arch Neurol 61 1 (2004) 35-38
172. Huang C.C., Yen T.C., Weng Y.H., et al. Normal dopamine transporter binding in dopa responsive dystonia. J Neurol 249 8 (2002) 1016-1020
173. Huang C.C., Weng Y.H., Lu C.S., et al. Dopamine transporter binding in chronic manganese intoxication. J Neurol 250 11 (2003) 1335-1339
174. Ku M.C., Huang C.C., Kuo H.C., et al. Diffuse white matter lesions in carbon disulfide intoxication: microangiopathy or demyelination. Eur Neurol 50 4 (2003) 220-224
175. Huang C.C. Carbon disulfide neurotoxicity: Taiwan experience. Acta Neurol Taiwan 13 1 (2004) 3-9
176. Hsiao M.C., Lin K.J., Liu C.Y., et al. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr Res 65 1 (2003) 39-46
177. Yang Y.K., Yu L., Yeh T.L., et al. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161 8 (2004) 1496-1498
178. Huang C.C., Chu N.S., Yen T.C., et al. Dopamine transporter binding in Wilson's disease. Can J Neurol Sci 30 2 (2003) 163-167
179. Lai S.C., Weng Y.H., Yen T.C., et al. Imaging early-stage corticobasal degeneration with [99mTc]TRODAT-1 SPET. Nucl Med Commun 25 4 (2004) 339-345
180. Lu C.S., Weng Y.H., Chen M.C., et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 45 1 (2004) 49-55
181. Swanson R.L., Newberg A.B., Acton P.D., et al. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Nucl Med Mol Imaging 32 3 (2005) 302-307
182. Mozley P.D., Acton P.D., Barraclough E.D., et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 40 11 (1999) 1812-1817
183. Mozley L.H., Gur R.C., Mozley P.D., et al. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158 9 (2001) 1492-1499
184. Krause K.H., Dresel S.H., Krause J., et al. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5 2 (2002) 111-113
185. Gardiner S.A., Morrison M.F., Mozley P.D., et al. Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy postmenopausal women. Am J Geriatr Psychiatry 12 6 (2004) 621-630